Question 1

What is mavorixafor?

Accepted Answer

Mavorixafor is a medication known as a CXCR4 antagonist. It works by blocking a specific protein called the CXCR4 receptor, which is involved in how certain white blood cells move and are distributed throughout the body.

By blocking this receptor, the medication helps control the release of these immune cells from the bone marrow into the bloodstream. This process is intended to help maintain healthier levels of white blood cells in circulation to support the immune system.

Question 2

What is mavorixafor used for?

Accepted Answer

mavorixafor is used to treat WHIM syndrome .

Question 3

How does mavorixafor work?

Accepted Answer

Mechanism of Action

Mavorixafor is a type of medication called a CXCR4 antagonist. It is used to treat WHIM syndrome, a rare genetic disorder where the immune system does not work correctly because white blood cells are not distributed properly throughout the body.

The Role of CXCR4

In a healthy body, a protein receptor called CXCR4 helps control how white blood cells move in and out of the bone marrow. In people with WHIM syndrome, a genetic mutation causes this receptor to be overactive. This overactivity acts like a signal that keeps white blood cells trapped inside the bone marrow instead of letting them enter the blood where they are needed to fight germs.

Releasing Immune Cells

Mavorixafor works by blocking the CXCR4 receptor. By turning off this overactive signal, the medication allows trapped immune cells to move out of the bone marrow and into the bloodstream. The primary cells affected include:

Neutrophils: Cells that are essential for fighting bacterial infections.

Lymphocytes: Cells that help the body recognize and respond to viruses and other pathogens.

By increasing the number of these white blood cells circulating in the blood, mavorixafor helps improve the body's ability to defend itself against recurrent and potentially serious infections.

Question 4

What are the brand names for mavorixafor?

Accepted Answer

mavorixafor is sold under the brand name Xolremdi .

Question 5

What are the active ingredients in mavorixafor?

Accepted Answer

The active ingredient in mavorixafor is mavorixafor .

Question 6

What are the side effects of mavorixafor?

Accepted Answer

Common side effects of mavorixafor may include:

The most common side effects reported by people taking mavorixafor include:

Low platelet counts (thrombocytopenia)

Skin rash

Stuffy or runny nose

Nosebleeds

Back pain

Some side effects can be serious. Contact your healthcare provider immediately if you experience symptoms of the following:

Severe Thrombocytopenia: A significant drop in platelets can increase your risk of bleeding. Your doctor will perform blood tests to monitor your platelet levels before starting and during treatment with this medication.

Allergic Reactions: Seek emergency medical help if you have signs of an allergic reaction, such as hives, swelling of the face or throat, or difficulty breathing.

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is mavorixafor?

Accepted Answer

mavorixafor belongs to the CXCR4 antagonist drug class.

Question 8

What is the dosage of mavorixafor and how do I take it?

Accepted Answer

How to Take This Medication

Mavorixafor is taken by mouth, usually once a day. It must be taken on an empty stomach to ensure the medicine is absorbed properly. This generally means taking the dose at least 30 minutes before a meal or at least 2 hours after eating.

When taking mavorixafor, keep the following in mind:

Swallow the capsules whole. Do not open, break, chew, or crush them.

Try to take your dose at the same time every day.

If you are taking other medications, your doctor may provide specific instructions on timing, as some drugs can interfere with how mavorixafor works.

Missed Dose

If you miss a dose, take it as soon as you remember. If it is nearly time for your next dose, skip the missed one and return to your regular schedule. Do not take extra medicine to make up for a missed dose.

Question 9

Is mavorixafor safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Based on findings from animal studies, mavorixafor may cause harm to a fetus. Healthcare providers typically verify pregnancy status in individuals of reproductive potential before starting treatment. It is important to use effective contraception during treatment and for at least 3 weeks after the final dose. If you become pregnant or think you might be pregnant while taking this medication, notify your doctor immediately.

Breastfeeding

It is not known if mavorixafor passes into human breast milk or how it might affect a nursing infant. Because of the potential for serious adverse reactions in a breastfed child, breastfeeding is not recommended during treatment and for 3 weeks after the last dose. Patients should discuss the risks and benefits of breastfeeding with their healthcare provider to determine the safest feeding plan for their infant.

Question 10

What forms and strengths does mavorixafor come in?

Accepted Answer

Mavorixafor is available in the following form:

Oral Capsule: This medication is taken by mouth as directed by a healthcare provider.

Question 11

What is the FDA approval status of mavorixafor?

Accepted Answer

The U.S. Food and Drug Administration (FDA) approved mavorixafor (brand name Xolremdi) on April 26, 2024. It is the first medication specifically approved to treat WHIM syndrome, a rare genetic disorder characterized by warts, hypogammaglobulinemia, infections, and myelokathexis.

Mavorixafor is indicated for use in adults and pediatric patients 12 years of age and older to increase the number of circulating mature neutrophils and lymphocytes.

The approval was based on results from the 4WHIM clinical trial, a 52-week study that demonstrated the drug's effectiveness in increasing white blood cell counts and reducing the frequency and severity of infections. During its development, the FDA granted mavorixafor several special designations, including:

Breakthrough Therapy designation

Orphan Drug designation

Priority Review

There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) required for mavorixafor. The FDA continues to monitor the drug's safety through standard post-marketing surveillance.

Question 12

What should I know about mavorixafor and cost?

Accepted Answer

Cost and Insurance Coverage

Specific pricing information for mavorixafor is not available in the provided clinical sources. The out-of-pocket cost for this medication will depend on individual insurance plans and pharmacy arrangements.

Factors that typically influence the cost of this specialty medication include:

Insurance Plan Details: Coverage levels, deductibles, and copayment amounts vary by plan.

Prior Authorization: Insurance companies often require a prior authorization process to confirm the medication is medically necessary for treating WHIM syndrome.

Specialty Pharmacy: Mavorixafor is generally available through specialty pharmacies, which may offer different pricing or support services compared to retail pharmacies.

Patients should consult their healthcare provider or insurance company for the most accurate and up-to-date cost information. Manufacturer-sponsored patient assistance programs may also be available to help with costs for eligible individuals.

mavorixafor

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Found an Error?